OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are as...
OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study
About this item
Full title
Author / Creator
Kostine, M. , Mauric, E. , Rouxel, L. , Barnetche, T. , Veillon, R. , Martin, F. , Dutriaux, C. , Dousset, L. , Pham-Ledard, A. , Prey, S. , Beylot-Barry, M. , Daste, A. , Gross-Goupil, M. , Lallier, J. , Ravaud, A. , Forcade, E. , Bannwarth, B. , Truchetet, M.-E. , Richez, C. , Mehsen-Cetre, N. and Schaeverbeke, T.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
BackgroundImmune checkpoint inhibitors (ICI) represent a new standard of care for the treatment of selected advanced cancers and are still being investigated in many other tumour types. By enhancing the T-cell activation, a unique spectrum of inflammatory side effects has emerged, also known as immune-related adverse events (irAEs), including vario...
Alternative Titles
Full title
OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2071177303
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2071177303
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2018-eular.3783
